Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
flutamide
In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its
antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding
of androgen in target tissues. Prostatic carcinoma is known to be androgen-sensitive
and responds to treatment that counteracts the effect of androgen and/or removes the
source of androgen. Elevations of plasma testosterone and estradiol levels have been
noted following administration of flutamide.
Flutamide is indicated* for use in combination with LHRH agonists for the management
of locally confined metastatic prostate cancer.
*Please refer to full prescribing information/package insert for precise indications.
